To Err is Human, to De-Risk Divine

We live in an age in which we wish to 'de-risk' our investments.  In the highly competitive pharmaceutical sector, if you don't spot potential risks before they become a danger to the patient, and the regulator can prove you had the information to mitigate them, you are liable to face one or more of the following: closure of your business unit, a prosecution case that could lead to a jail sentence, and personal responsibility for the serious illness or death of a patient.  The need to de-risk is obvious.

Never before has it been so important for clinical trials teams to be alert for signals that point them toward possible risks.  Clinical teams should avoid the trap of being locked into rules, regulations, and habits that mean they are failing to pay attention to all available evidence about the potential risks of a trial or product. 

To read the article in full please click on the pdf link below:

How to build risk management into Clinical Trials

If you would like any further information please contact Kate Adams at kate.adams@wcigroup.com

About The Monitor magazine
The Monitor is published by the Association of Clinical Research Professionals.  Each issue includes both solicited and unsolicited peer reviewed articles, columns, editorials and Chapter and Forum news.

For further information about the publication please visit the ACRP website at www.acrpnet.org